The Transcriptional Landscape of Coding and Noncoding RNAs in Recurrent and Nonrecurrent Colon Cancer
The American Journal of Pathology, ISSN: 0002-9440, Vol: 194, Issue: 8, Page: 1424-1442
2024
- 3Captures
- 11Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
- Mentions11
- News Mentions10
- News10
- Blog Mentions1
- Blog1
Most Recent Blog
RNAs may help identify stage II colon cancer patients who may benefit from chemotherapy following surgery
The decision to treat patients with stage II colon cancer with adjuvant chemotherapy remains controversial. Therefore, there is an urgent need to identify reliable prognostic biomarkers that may be used to identify which patients would benefit from chemotherapy following surgery. In a ground-breaking study investigators assess the biomarker potential of RNAs in stage II colon cancer. Their finding
Most Recent News
RNAs May Help to Identify Patients With Stage II Colorectal Cancer Who May Benefit From Adjuvant Chemotherapy
Investigators have assessed whether RNAs can be used as a biomarker to predict which patients with stage II colorectal cancer may benefit from postsurgical chemotherapy,
Article Description
A number of patients with colon cancer with local or local advanced disease suffer from recurrence and there is an urgent need for better prognostic biomarkers in this setting. Here, the transcriptomic landscape of mRNAs, long noncoding RNAs, snRNAs, small nucleolar RNAs (snoRNAs), small Cajal body–specific RNAs, pseudogenes, and circular RNAs, as well as RNAs denoted as miscellaneous RNAs, was profiled by total RNA sequencing. In addition to well-known coding and noncoding RNAs, differential expression analysis also uncovered transcripts that have not been implicated previously in colon cancer, such as RNA5SP149, RNU4-2, and SNORD3A. Moreover, there was a profound global up-regulation of snRNA pseudogenes, snoRNAs, and rRNA pseudogenes in more advanced tumors. A global down-regulation of circular RNAs in tumors relative to normal tissues was observed, although only a few were expressed differentially between tumor stages. Many previously undescribed transcripts, including RNU6-620P, RNU2-20P, VTRNA1-3, and RNA5SP60, indicated strong prognostic biomarker potential in receiver operating characteristics analyses. In summary, this study unveiled numerous differentially expressed RNAs across various classes between recurrent and nonrecurrent colon cancer. Notably, there was a significant global up-regulation of snRNA pseudogenes, snoRNAs, and rRNA pseudogenes in advanced tumors. Many of these newly discovered candidates demonstrate a strong prognostic potential for stage II colon cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002944024001639; http://dx.doi.org/10.1016/j.ajpath.2024.04.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85196019833&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38704091; https://linkinghub.elsevier.com/retrieve/pii/S0002944024001639; https://dx.doi.org/10.1016/j.ajpath.2024.04.003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know